Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy

Biochemical Journal

Volumn 409, Issue 2, 2008, Pages 439-447

  Devanur, Lakshmi D ^a   Evans, Robert W ^a   Evans, Patricia J ^b   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Deferiprone; Desferrioxamine (DFO); Hydroxypyridin 4 one (HPO); Iron chelation; Scavenging activity; Transferrin

Indexed keywords

AMINES; BLOOD; CHELATION; SPECTROSCOPIC ANALYSIS;

DEFERIPRONE; DESFERRIOXAMINE (DFO); IRON CHELATION THERAPY; SCAVENGING ACTIVITY; TRANSFERRIN;

IRON;

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; IRON; PYRIDINE DERIVATIVE; TRANSFERRIN;

ARTICLE; CHELATION THERAPY; IRON CHELATION; IRON TRANSPORT; PRIORITY JOURNAL; SPECTROSCOPY;

DEFEROXAMINE; IRON; IRON CHELATING AGENTS; PYRIDONES; TIME FACTORS; TRANSFERRIN;

EID: 38749092971     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070823     Document Type: Article

References (33)

1. Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J. et al. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 167, 3455-3462
2. 3+ values. Transfus. Sci. 23, 201-209
3. Peng, C-T., Chow, K-C., Chen, J-H., Chiang, Y-P., Lin, T-Y. and Tsai, C-H. (2003) Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur. J. Haematol. 76, 392-397
4. Kalinowski, D. S. and Richardson, D. R. (2007) Future of toxicology-iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy. Chem. Res. Toxicol. 26, 715-720
5. Gaeta, A. and Hider, R. C. (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146, 1041-1059
6. Boddaert, N., Le Quan Sang, K. H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J-C., Munnich, A. and Cabantchik., Z. I. (2007) Selective iron chelation in Friedreich ataxia: biological and clinical implications. Blood 110, 401-408
7. Grady, R. W., Bardoukas, V. A and Giardina, P. J. (1998) Iron chelation: combined therapy could be a better approach. Blood 92 (suppl 1), 16b
8. Schubert, J. and Derr, S. K. (1978) Mixed ligand therapy for plutonium and cadmium poisoning. Nature 275, 311-313
9. Evans, R. W., Sharma, M., Ogwang, W., Patel, K. J., Bartlett, A. N. and Kontoghiorghes, G. J. (1992) The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today 28, (suppl A), 19-23
10. Pollack, S., Aisen, P., Lasky, F. D. and Vanderhoff, G. (1976) Chelate mediated transfer of iron from transferrin to desferrioxamine. Br. J. Haematol. 34, 231-235
11. Pollack, S., Vanderhoff, G. and Lasky, F. (1977) Iron removal from transferrin. An experimental study. Biochim. Biophys. Acta 497, 481-487
12. Dobbin, P. S., Hider, R. C., Hall, A. D., Taylor, P. D., Sarpong, P., Porter, J. B., Xiao, G. and van der Helm, D. (1993) Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)- pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36, 2448-2458
13. Liu, Z. D., Kayyali, R., Hider, R. C., Porter, J. B. and Theobald, A. E. (2002) Design, synthesis and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: Structure-activity investigation of metalloenzymes inhibition by iron chelators. J. Med. Chem. 45, 631-639
14. Liu, Z. D. and Hider, R. C. (2002) Design of clinically useful iron(III) selective chelators. Med. Res. Rev. 22, 26-64
15. Piyamongkol, S. (2001) The design and synthesis of 3-hydroxide-4-one chelators, Ph.D. Thesis, University of London, London, U.K.
16. Piyamongkol S., Liu Z. D. and Hider, R. C. (2001) Novel synthetic approach to 2-(1′-hydroxyalkyl)- and 2-amido-3-hydroxypyridin-4-ones. Tetrahedron 57, 3479-3486
17. Dawson, R. M. C., Elliott, D. C., Elliott, W. H. and Jones, K. M. (1986) Data for Biochemical Research, Oxford University, Oxford.
18. Rose, J. (1964) Advanced Physico-chemical Experiments: A Textbook of Practical Physical Chemistry and Calculations, pp, 153-157, Sir Isaac Pitman & Sons, London.
19. Evans, R. W and Williams, J. (1980) The electrophoresis of transferrins in urea/polyacrylamide gels. Biochem. J. 189, 541-546
20. Alderighi, L., Gans, P., Ienco, A., Peters, D., Sabatini, A. and Vacca, A. (1999) Hyperguad simulation and speciation (HySS): a utility program for the investigation of equilibria involving soluble and partially soluble species. Coord. Chem. Rev. 184, 311-318
21. Baes, C. F. and Mesmer, R. E. (1976) The Hydrolysis of Cations, John Wiley & Sons, New York.
22. Motekaitis, R. J. and Martell, A. E. (1991) Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorg. Chim. Acta. 183, 71-80
23. 3+ values. J. Med. Chem. 42, 4814-4823
24. Kontoghiorghes, G. J., Goddard, J. G., Bartlett, A. N. and Sheppard, L. (1990) Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin. Pharmacol. Ther 48, 255-261
25. Porter, J. B. (2001) Deferoxamine Pharmacokinetics. Semin. Hematol. 38, (1 Suppl 1), 63-68
26. Gomber, S., Saxena, R. and Madan, N. (2004) Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 41, 21-27
27. Devanur, L. D., Neubert, H. and Hider, R. C. (2007) The Fenton activity of iron(III) in the presence of deferiprone, J. Pharm. Sci., doi: 10.1002/jps.21039
28. Evans, R. W., Rafique, R., Zarea, A., Rapisarda, C., Cammack, R., Evans, P. J., Porter, J. B. and Hider, R. C. (2007) Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera, J. Biol. Inorg. Chem., doi: 10.1007/s00775-007-0297-8
29. Abeysinghe, R. D., Roberts, P. J., Cooper, C. E., Maclean, K. H., Hider, R. C. and Porter, J. B. (1996) The environment of the lipoxygenase iron-binding site explored with novel hydroxypyridinone iron chelators. J. Biol. Chem. 271, 7965-7972
30. Cooper, C. E., Lynagh, G. R., Hoyes, K. P., Hider, R. C., Cammack, R. and Porter, J. B. (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 271, 20291-20299
31. Waldmeier, P. C, Buchle, A-M. and Steulet, A-F. (1993) Inhibition of catechol-o-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4- one (L1,CP20), in rat brain in vivo. Biochem. Pharmacol. 45, 2417-2424
32. Fabio, G., Minonzio, F., Delbini, P., Bianchi, A. and Cappellini, M. D. (2007) Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 109, 362-364
33. Link, G., Konijn, A. M., Breuer, W., Cabantchik, Z. I. and Hersko, C. (2001) Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rate heart cells in culture. J. Lab. Clin. Med. 138, 130-138